These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11488064)

  • 1. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
    Xu Y; McKenna RW; Molberg KH; Kroft SH
    Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
    Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
    Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
    Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
    Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
    Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.
    King BE; Chen C; Locker J; Kant J; Okuyama K; Falini B; Swerdlow SH
    Mod Pathol; 2000 Nov; 13(11):1219-31. PubMed ID: 11106080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas.
    Xu Y; McKenna RW; Kroft SH
    Mod Pathol; 2002 Apr; 15(4):413-9. PubMed ID: 11950915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
    Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.
    Zhao XF; Young KH; Frank D; Goradia A; Glotzbecker MP; Pan W; Kersun LS; Leahey A; Dormans JP; Choi JK
    Am J Clin Pathol; 2007 Jan; 127(1):47-54. PubMed ID: 17145622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH.
    Chuang SS; Ye H; Du MQ; Lu CL; Dogan A; Hsieh PP; Huang WT; Jung YC
    Am J Clin Pathol; 2007 Oct; 128(4):558-64. PubMed ID: 17875505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
    Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
    Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.